168 related articles for article (PubMed ID: 10854579)
21. Antagonism of metabotropic glutamate receptor type 5 attenuates l-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease.
Mela F; Marti M; Dekundy A; Danysz W; Morari M; Cenci MA
J Neurochem; 2007 Apr; 101(2):483-97. PubMed ID: 17359492
[TBL] [Abstract][Full Text] [Related]
22. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
Alachkar A; Brotchie JM; Jones OT
Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats.
Yamada H; Aimi Y; Nagatsu I; Taki K; Kudo M; Arai R
Neurosci Res; 2007 Sep; 59(1):1-7. PubMed ID: 17586078
[TBL] [Abstract][Full Text] [Related]
24. SCH 23390 enhances exogenous L-DOPA decarboxylation in nigrostriatal neurons.
Neff NH; Wemlinger TA; Hadjiconstantinou M
J Neural Transm (Vienna); 2000; 107(4):429-43. PubMed ID: 11215754
[TBL] [Abstract][Full Text] [Related]
25. Dopa-decarboxylation in the striata of rats with unilateral substantia nigra lesions.
Kang UJ; Park DH; Wessel T; Baker H; Joh TH
Neurosci Lett; 1992 Nov; 147(1):53-7. PubMed ID: 1480324
[TBL] [Abstract][Full Text] [Related]
26. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Van De Witte SV; Groenewegen HJ; Voorn P
Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
[TBL] [Abstract][Full Text] [Related]
27. Some central effects of CGP 37849 and CGP 39551, the competitive NMDA receptor antagonists: potential antiparkinsonian activity.
Maj J; Skuza G; Rogóz Z
J Neural Transm Park Dis Dement Sect; 1993; 6(1):53-62. PubMed ID: 8105798
[TBL] [Abstract][Full Text] [Related]
28. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment.
Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK
Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552
[TBL] [Abstract][Full Text] [Related]
29. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
[TBL] [Abstract][Full Text] [Related]
30. 6-Hydroxydopamine lesion of locus coeruleus and the antiparkinsonian potential of NMDA-receptor antagonists in rats.
Rückert N; Bubser M; Schmidt WJ
J Neural Transm (Vienna); 1997; 104(4-5):363-77. PubMed ID: 9295171
[TBL] [Abstract][Full Text] [Related]
31. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat.
Nash JE; Hill MP; Brotchie JM
Exp Neurol; 1999 Jan; 155(1):42-8. PubMed ID: 9918703
[TBL] [Abstract][Full Text] [Related]
32. Effect of pyridoxal phosphate deficiency on aromatic L-amino acid decarboxylase activity with L-DOPA and L-5-hydroxytryptophan as substrates in rats.
Rahman MK; Nagatsu T; Sakurai T; Hori S; Abe M; Matsuda M
Jpn J Pharmacol; 1982 Oct; 32(5):803-11. PubMed ID: 6983619
[TBL] [Abstract][Full Text] [Related]
33. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys.
Hadj Tahar A; Grégoire L; Darré A; Bélanger N; Meltzer L; Bédard PJ
Neurobiol Dis; 2004 Mar; 15(2):171-6. PubMed ID: 15006686
[TBL] [Abstract][Full Text] [Related]
34. Effect of pyridoxine deficiency on aromatic L-amino acid decarboxylase in adult rat brain.
Siow YL; Dakshinamurti K
Exp Brain Res; 1985; 59(3):575-81. PubMed ID: 3875501
[TBL] [Abstract][Full Text] [Related]
35. Vesicular monoamine transporter-2 and aromatic L-amino acid decarboxylase gene therapy prevents development of motor complications in parkinsonian rats after chronic intermittent L-3,4-dihydroxyphenylalanine administration.
Lee WY; Lee EA; Jeon MY; Kang HY; Park YG
Exp Neurol; 2006 Jan; 197(1):215-24. PubMed ID: 16269145
[TBL] [Abstract][Full Text] [Related]
36. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo.
Danielsen EH; Smith D; Hermansen F; Gjedde A; Cumming P
Synapse; 2001 Aug; 41(2):172-5. PubMed ID: 11400183
[TBL] [Abstract][Full Text] [Related]
37. A kinetic analysis of Drosophila melanogaster dopa decarboxylase.
Black BC; Smarrelli J
Biochim Biophys Acta; 1986 Mar; 870(1):31-40. PubMed ID: 3081033
[TBL] [Abstract][Full Text] [Related]
38. Use of radiolabeled monofluoromethyl-Dopa to define the subunit structure of human L-Dopa decarboxylase.
Maneckjee R; Baylin SB
Biochemistry; 1983 Dec; 22(26):6058-63. PubMed ID: 6661425
[TBL] [Abstract][Full Text] [Related]
39. NR2A and NR2B subunit containing NMDA receptors differentially regulate striatal output pathways.
Fantin M; Marti M; Auberson YP; Morari M
J Neurochem; 2007 Dec; 103(6):2200-11. PubMed ID: 17986236
[TBL] [Abstract][Full Text] [Related]
40. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
Carta AR; Pinna A; Tronci E; Morelli M
Neurology; 2003 Dec; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
